UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Journal of clinical oncology, 2019-04, Vol.37 (12), p.992-1000

2019

Volltextzugriff (PDF)

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Volltextzugriff (PDF)

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Journal of clinical oncology, 2019-10, Vol.37 (30), p.2738-2745

2019

Volltextzugriff (PDF)

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2011, Vol.377 (9780), p.1846-1854

2011

Volltextzugriff (PDF)

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Nature communications, 2016-06, Vol.7 (1), p.11815-15, Article 11815

2016

Volltextzugriff (PDF)

Molecular pathways and therapeutic targets in lung cancer

Oncotarget, 2014-03, Vol.5 (6), p.1392-1433

2014

Volltextzugriff (PDF)

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

JCO precision oncology, 2019-12 (3), p.1-9

2019

Volltextzugriff (PDF)

Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma

Journal of thoracic oncology, 2018-08, Vol.13 (8), p.1204-1212

2018

Volltextzugriff (PDF)

Agents to treat BRAF- mutant lung cancer

Drugs in Context, 2019, Vol.8, p.212566-5

2019

Volltextzugriff (PDF)

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

BMC cancer, 2020-05, Vol.20 (1), p.383-13, Article 383

2020

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100332-100332, Article 100332

2022

Volltextzugriff (PDF)

A novel classification of lung cancer into molecular subtypes

PloS one, 2012-02, Vol.7 (2), p.e31906-e31906

2012

Volltextzugriff (PDF)

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer

Biochemical and biophysical research communications, 2009-10, Vol.388 (3), p.483-489

2009

Volltextzugriff (PDF)

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

Journal of cancer research and clinical oncology, 2023-05, Vol.149 (5), p.2235-2242

2023

Volltextzugriff (PDF)

Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort

Cancer, 2013-02, Vol.119 (4), p.847-853

2013

Volltextzugriff (PDF)

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer

Molecular cancer therapeutics, 2016-09, Vol.15 (9), p.2244-2250

2016

Volltextzugriff (PDF)

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2015-11, Vol.20 (11), p.1298-1303

2015

Volltextzugriff (PDF)

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

Lung cancer (Amsterdam, Netherlands), 2012-06, Vol.76 (3), p.393-396

2012

Volltextzugriff (PDF)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

The New England journal of medicine, 2018-05, Vol.378 (22), p.2093-2104

2018

Volltextzugriff (PDF)

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Drugs in Context, 2019, Vol.8, p.212578-6

2019

Volltextzugriff (PDF)

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

Cardio-oncology (London, England), 2023-01, Vol.9 (1), p.4-6, Article 4

2023

Volltextzugriff (PDF)

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database

Radiation oncology (London, England), 2018-10, Vol.13 (1), p.196-196, Article 196

2018

Volltextzugriff (PDF)

Epigenetic Regulation of the Tumor Suppressor Gene TCF21 on 6q23-q24 in Lung and Head and Neck Cancer

Proceedings of the National Academy of Sciences - PNAS, 2006-01, Vol.103 (4), p.982-987

2006

Volltextzugriff (PDF)

Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients

Journal of clinical oncology, 2006-04, Vol.24 (12), p.1852-1859

2006

Volltextzugriff (PDF)

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Journal of clinical oncology, 2021-07, Vol.39 (21), p.JCO2003579-2338

2021

Volltextzugriff (PDF)

1 – 25 von 345

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(328)
Mit Volltextzugriff
(288)

Publikationsform

Artikel
(342)
Berichte
(3)

Sprache

Englisch
(345)

Erscheinungsjahr

n.n

Thema

Science & Technology
(177)
Life Sciences & Biomedicine
(167)
Humans
(163)
Oncology
(137)
Female
(79)
Male
(78)
Middle Aged
(68)
Aged
(64)
Lung Cancer
(54)
Lung Neoplasms - Pathology
(49)
Adult
(46)
Lung Neoplasms - Drug Therapy
(45)
Biological And Medical Sciences
(42)
Aged, 80 And Over
(35)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(35)
Tumors
(34)
Lung Neoplasms - Genetics
(33)
Medical Sciences
(33)
Respiratory System
(33)
Carcinoma, Non-Small-Cell Lung - Pathology
(32)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients

Molecular pathways and therapeutic targets in lung cancer

Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non–Small-Cell Lung Cancer Using a Decision Analytic Model

Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma

Agents to treat BRAF- mutant lung cancer

Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

A novel classification of lung cancer into molecular subtypes

MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer

Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival

Smoking status and survival in the national comprehensive cancer network non–small cell lung cancer cohort

A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer

Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib‐Responsive Non‐Small Cell Lung Cancer

Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Reversible cardiomyopathy in a patient with chronic myelomonocytic leukemia treated with decitabine/cedazuridine: a case report

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database

Epigenetic Regulation of the Tumor Suppressor Gene TCF21 on 6q23-q24 in Lung and Head and Neck Cancer

Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Suchergebnisse filtern